Yesterday, Jan. 13, 2016, 39 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.56 to $2,760,975.00.

Highlighted Stocks Traded by Insiders:

Gevo (GEVO) - FREE Research Report

Gruber Patrick R., who is Chief Executive Officer at Gevo, sold 108 shares at $0.41 on Jan. 13, 2016. Following this transaction, the Chief Executive Officer owned 37,925 shares meaning that the stake was reduced by 0.28% with the 108-share transaction.

Ryan Christopher Michael, who is President and COO at Gevo, sold 141 shares at $0.41 on Jan. 13, 2016. Following this transaction, the President and COO owned 32,893 shares meaning that the stake was reduced by 0.43% with the 141-share transaction.

Roda Gregory, who is Chief Commercial Officer at Gevo, sold 16 shares at $0.41 on Jan. 13, 2016. Following this transaction, the Chief Commercial Officer owned 7,348 shares meaning that the stake was reduced by 0.22% with the 16-share transaction.

Willis Mike, who is Cfo at Gevo, sold 21 shares at $0.41 on Jan. 13, 2016. Following this transaction, the Cfo owned 22,754 shares meaning that the stake was reduced by 0.09% with the 21-share transaction.

The shares most recently traded at $0.40, down $0.01, or 2.5% since the insider transaction. Historical insider transactions for Gevo go as follows:

  • 4-Week # shares bought: 181,484
  • 4-Week # shares sold: 118
  • 12-Week # shares bought: 181,484
  • 12-Week # shares sold: 1,486
  • 24-Week # shares bought: 181,484
  • 24-Week # shares sold: 4,551

The average volume for Gevo has been 602,500 shares per day over the past 30 days. Gevo has a market cap of $7.0 million and is part of the basic materials sector and chemicals industry. Shares are down 35.48% year-to-date as of the close of trading on Wednesday.

Gevo, Inc., a renewable chemicals and biofuels company, focuses on the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The company operates in two segments, Gevo, Inc.; and Gevo Development/Agri-Energy. Currently, there is 1 analyst who rates Gevo a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GEVO - FREE

TheStreet Quant Ratings rates Gevo as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and generally disappointing historical performance in the stock itself. Get the full Gevo Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Exact (EXAS) - FREE Research Report

Thompson David, who is Director at Exact, bought 15,000 shares at $6.99 on Jan. 13, 2016. Following this transaction, the Director owned 110,213 shares meaning that the stake was boosted by 15.75% with the 15,000-share transaction.

The shares most recently traded at $6.77, down $0.22, or 3.25% since the insider transaction. Historical insider transactions for Exact go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 8,015
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 8,015
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 8,015

The average volume for Exact has been 2.7 million shares per day over the past 30 days. Exact has a market cap of $707.1 million and is part of the health care sector and health services industry. Shares are down 27.41% year-to-date as of the close of trading on Wednesday.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. Currently, there are 8 analysts who rate Exact a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EXAS - FREE

TheStreet Quant Ratings rates Exact as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Exact Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Curtiss-Wright (CW) - FREE Research Report

Sihler William W Dr, who is Director at Curtiss-Wright, sold 4,827 shares at $70.00 on Jan. 13, 2016. Following this transaction, the Director owned 6,724 shares meaning that the stake was reduced by 41.79% with the 4,827-share transaction.

The shares most recently traded at $68.68, down $1.32, or 1.92% since the insider transaction. Historical insider transactions for Curtiss-Wright go as follows:

  • 4-Week # shares sold: 1,100
  • 12-Week # shares sold: 1,100
  • 24-Week # shares sold: 8,600

The average volume for Curtiss-Wright has been 239,200 shares per day over the past 30 days. Curtiss-Wright has a market cap of $3.2 billion and is part of the industrial goods sector and industrial industry. Shares are up 0.77% year-to-date as of the close of trading on Wednesday.

Curtiss-Wright Corporation provides engineered products and services to the defense, power generation, oil and gas, commercial aerospace, and general industrial markets worldwide. It operates through three segments: Flow Control, Controls, and Surface Technologies. The stock currently has a dividend yield of 0.74%. The company has a P/E ratio of 20.3. Currently, there are 6 analysts who rate Curtiss-Wright a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CW - FREE

TheStreet Quant Ratings rates Curtiss-Wright as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Curtiss-Wright Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.